- Home
- STTK vs LFT Comparison
STTK vs LFT Comparison
Compare STTK & LFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- LFT
- Stock Information
- Founded
- STTK 2016
- LFT 2012
- Country
- STTK United States
- LFT United States
- Employees
- STTK N/A
- LFT N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- LFT Real Estate Investment Trusts
- Sector
- STTK Health Care
- LFT Real Estate
- Exchange
- STTK Nasdaq
- LFT Nasdaq
- Market Cap
- STTK 112.6M
- LFT 92.1M
- IPO Year
- STTK 2020
- LFT N/A
- Fundamental
- Price
- STTK $1.98
- LFT $1.80
- Analyst Decision
- STTK Hold
- LFT Hold
- Analyst Count
- STTK 5
- LFT 1
- Target Price
- STTK $3.00
- LFT N/A
- AVG Volume (30 Days)
- STTK 411.4K
- LFT 161.6K
- Earning Date
- STTK 11-13-2025
- LFT 11-11-2025
- Dividend Yield
- STTK N/A
- LFT 13.48%
- EPS Growth
- STTK N/A
- LFT N/A
- EPS
- STTK N/A
- LFT 0.18
- Revenue
- STTK $2,997,000.00
- LFT $25,803,999.00
- Revenue This Year
- STTK N/A
- LFT $124.75
- Revenue Next Year
- STTK N/A
- LFT N/A
- P/E Ratio
- STTK N/A
- LFT $9.89
- Revenue Growth
- STTK N/A
- LFT N/A
- 52 Week Low
- STTK $0.69
- LFT $1.75
- 52 Week High
- STTK $2.71
- LFT $2.84
- Technical
- Relative Strength Index (RSI)
- STTK 48.57
- LFT 32.43
- Support Level
- STTK $1.72
- LFT $1.76
- Resistance Level
- STTK $2.71
- LFT $1.88
- Average True Range (ATR)
- STTK 0.22
- LFT 0.06
- MACD
- STTK -0.09
- LFT -0.00
- Stochastic Oscillator
- STTK 25.05
- LFT 17.24
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.